Literature DB >> 6327483

Hepatitis B viral nucleotide sequences in non-A, non-B or hepatitis B virus-related chronic liver disease.

A Figus, H E Blum, G N Vyas, S De Virgilis, A Cao, M Lippi, E Lai, A Balestrieri.   

Abstract

The presence of serological markers of hepatitis B virus (HBV) infection and of hepatocellular HBV DNA were investigated in 19 HBsAg-negative patients with clinically and histologically significant chronic liver disease. Four cases negative for antibodies to HBsAg (anti-HBs), to the core antigen (anti-HBc), and to the e antigen (anti-HBe) were classified as non-A, non-B hepatitis. The remainder, positive for one or more of the three antibodies, were classified as hepatitis B. Histologic diagnosis was chronic active hepatitis in five, chronic persistent hepatitis in 11, micronodular cirrhosis in two, and fatty liver in one patient. The DNA extracted from limited amounts of liver biopsies, without cleavage by restriction endonucleases, was analyzed by the Southern blot technique for the presence of episomal HBV DNA. Autoradiographs showed a single band of less than 4.0 kilobase (kb) corresponding to the monomeric form of HBV DNA in five patients, several bands of larger forms (4.0 to 18.0 kb) in three patients, both the monomeric and the larger forms in eight patients, and no HBV DNA in three patients. While HBV DNA was detected in the hepatocellular DNA of six patients who underwent splenectomy, hybridization was negative with the DNA extracted from their spleens. The episomal viral DNA larger than 4.0 kb may represent concatemeric forms or free oligomers which could not be distinguished from rearranged and/or integrated viral DNA in the limited analyses of the hepatocellular DNA hydrolyzed with HindIII or EcoRI. Our observations suggest the presence of HBV-like agents in the liver of serologically HBsAg-negative patients with chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327483     DOI: 10.1002/hep.1840040303

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Detection of HBV DNA in non-A, non-B hepatic tissues using the polymerase chain reaction assay.

Authors:  S Ohkoshi
Journal:  Gastroenterol Jpn       Date:  1991-12

2.  Evidence against a requisite role for defective virus in the establishment of persistent hepadnavirus infections.

Authors:  R H Miller; R Girones; P J Cote; W E Hornbuckle; T Chestnut; B H Baldwin; B E Korba; B C Tennant; J L Gerin; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  In vitro amplification of hepatitis B virus sequences from liver tumour DNA and from paraffin wax embedded tissues using the polymerase chain reaction.

Authors:  Y M Lo; W Z Mehal; K A Fleming
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

4.  Geographical variation in prevalence of hepatitis B virus DNA in HBsAg negative patients.

Authors:  Y M Lo; E S Lo; W Z Mehal; M Sampietro; G Fiorelli; G Ronchi; C H Tse; K A Fleming
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

5.  Sequence analysis of hepatitis B virus DNA in immunologically negative infection.

Authors:  S Preisler-Adams; H J Schlayer; T Peters; F Hettler; W Gerok; J Rasenack
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

6.  Hepatitis B virus markers and antibodies to hepatitis C virus in Japanese patients with hepatocellular carcinoma.

Authors:  N Yuki; N Hayashi; A Kasahara; H Hagiwara; K Katayama; H Fusamoto; T Kamada
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

7.  HBsAg clearance in chronic active hepatitis B. A possible cause of cryptogenic cirrhosis.

Authors:  T R Morgan; A G Redeker; S Yamada; M Ashcavai
Journal:  Dig Dis Sci       Date:  1986-07       Impact factor: 3.199

8.  Frequency of hepatic HBV-DNA in patients with cirrhosis and hepatocellular carcinoma: relation to serum HBV markers.

Authors:  Y S White; P J Johnson; F Davison; R Williams
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.